ALX Oncology announces data from Phase 2 trial of evorpacept

ALX Oncology (ALXO) announced that positive data from a Phase 2 investigator-sponsored trial of evorpacept, in combination with standard-of-care rituximab and lenalidomide, for patients with indolent B-cell non-Hodgkin lymphoma is being presented Sunday, December 7 during a poster presentation at the American Society of Hematology Annual Meeting 2025 in Orlando, Florida. The clinical trial enrolled a total of 24 patients with previously untreated iNHL, 14 patients with follicular lymphoma and 10 patients with marginal zone lymphoma. The primary objective of best CR rate above 80% was met with evorpacept added to R2 in the context of a historical R2 CR rate of 50%. The investigators found the addition of evorpacept to R2 to be a well-tolerated frontline non-chemotherapy regimen for patients with iNHL, resulting in a high CR rate. 92% of patients achieved a complete response, and 8% achieved a partial response, with the overall response rate being 100%. One year progression free survival rate was 91%, and one year overall survival rate was 100%.